Just before the summer, the Minister of Health and Social Services listed Movapo (apomorphine hydrochloride) on the RAMQ’s list of drugs. This means that a new reimbursable drug is now available in the therapeutic arsenal of neurologists.
This new adjunctive drug is intended to treat the off-cycle of patients who are already receiving optimized dopamine therapy.
In order to access this new treatment, you must consult a specialized neurologist. If the doctor considers this treatment is relevant to you, he or she will return you to his or her clinic for a one-day test period to determine the optimal dose to resolve your “off” periods.
To be reimbursed, your neurologist will have to fill out a form and send it to the RAMQ so that you will only have to pay the monthly deductible, unless you have already reached the maximum that is $93 per month.
Please do not make any changes to your treatment regimen without first discussing with a health care professional. Remember that your doctor or pharmacist can always help you manage your medication.
Parkinson Québec ensures that the best therapeutic options are available for Quebecers with Parkinson’s disease. If you have any questions about this product or other issues affecting the Parkinson community, contact Parkinson Québec by phone at 1-800-720-1307 or by email at info@parkinsonquebec.ca